Comparative Pharmacology
Head-to-head clinical analysis: MELLARIL S versus TREMIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MELLARIL S versus TREMIN.
MELLARIL-S vs TREMIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thioridazine is a typical antipsychotic that blocks postsynaptic dopamine D2 receptors in the mesolimbic pathway, also exhibiting alpha-adrenergic blockade and anticholinergic effects.
Trihexyphenidyl is a centrally acting anticholinergic agent that blocks muscarinic acetylcholine receptors in the basal ganglia, restoring the balance between dopaminergic and cholinergic activity, thereby reducing extrapyramidal symptoms.
Initial 50-100 mg orally 3 times daily, titrate to 200-600 mg/day in divided doses; maximum 800 mg/day for severe psychosis.
1 mg orally 1-2 times daily, gradually increasing by 1 mg every 5-7 days up to 12 mg/day in divided doses. Maximum dose 12 mg/day.
None Documented
None Documented
Terminal elimination half-life: 10–20 hours (mean ~15 hours). Clinical context: Steady-state achieved within 4–5 days; allows once-daily or twice-daily dosing.
Terminal elimination half-life: 16 hours (range 12–20 hours) in adults, supporting twice-daily dosing; 35 hours in elderly patients
Primarily renal (approximately 70%) as metabolites (sulfoxides and glucuronides); about 30% excreted in feces via bile. Less than 1% excreted unchanged.
Renal: 40% unchanged; fecal: 60% as metabolites
Category C
Category C
Antipsychotic
Antipsychotic